Development of polypeptide-based materials toward messenger RNA delivery

Abstract

Messenger RNA (mRNA)-based therapeutic agents have demonstrated significant potential in recent times, particularly in the context of the COVID-19 pandemic outbreak. As a promising prophylactic and therapeutic strategy, polypeptide-based mRNA...

Tuneable redox-responsive albumin-hitchhiking drug delivery to tumours for cancer treatment

“…Significant advances in classical cancer treatment modalities, including chemotherapy, radiotherapy, and surgery, have contributed to a decline in cancer mortality rates in recent decades; however, cancer remains the second most common cause of death in the USA, with an estimated 609 820 deaths in 2023. 1–3 Small molecular drugs play a pivotal role in treating cancer, but many of these small molecular drugs, such as camptothecin (CPT), monomethyl auristatin E (MMAE), and mertansine (DM1), suffer from limited solubility, severe side effects, and unsatisfactory efficacy due to unfavourable pharmacokinetics and inefficient drug delivery to diseased sites. 4–6 Drug delivery systems, including polymeric micelles, liposomes, polymer–drug conjugates, antibody–drug conjugates, and nanoparticles, have been widely used to improve pharmacokinetics and biodistribution, ultimately leading to enhanced therapeutical efficacy and reduced adverse effects.…”